SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Merrimack Pharmaceuticals, Inc. (MACK)

MACK RSS Feed
Add MACK Price Alert      Hide Sticky   Hide Intro
Moderator: $Pistol Pete$
Search This Board: 
Last Post: 8/16/2017 7:58:58 AM - Followers: 69 - Board type: Free - Posts Today: 0



Welcome to Merrimack Pharmaceuticals, Inc. (MACK) Board!!!



At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.

 

       Our Leadership

           Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare                  industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and                    private  management from Yale University and a BA from Stanford University.

           Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008            to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and                        specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA            in theology from Cambridge University and a BA from Cambridge University.

           Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice                  specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010.                Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins            holds an  MBA and a BS from McGill University.

           Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at                the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after                    serving on the  faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems            biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.

           William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business            services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From                        September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and              a BA from Williams College.

           Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009            to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational                models of  signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in                  Germany.

           Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development                roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University                and a BS from  Bates College.

          William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of               Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007.             Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional                             Accounting and a BA from Williams College.
 

     Contact Us

        One Kendall Square
        Building 700, Suite B7201
        Cambridge, MA 02139
        Phone: 617-441-1000
 




 

 

MACK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MACK News: Current Report Filing (8-k) 08/14/2017 10:07:25 AM
MACK News: Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer 08/14/2017 06:55:00 AM
MACK News: Quarterly Report (10-q) 08/09/2017 04:32:11 PM
MACK News: Current Report Filing (8-k) 08/09/2017 07:40:45 AM
MACK News: Merrimack Reports Second Quarter 2017 Financial Results 08/09/2017 06:55:00 AM
PostSubject
#601  Sticky Note $MACK Merrimack Declares $140M Special Dividend in Connection $Pistol Pete$ 04/13/17 10:54:58 AM
#828   $MACK Daily and Weekly Charts http://www.stock $Pistol Pete$ 08/16/17 07:58:58 AM
#827   Merrimack Pharmaceuticals (NASDAQ:MACK): Q2 EPS of -$0.22 misses roger wilco 08/09/17 09:27:36 AM
#826   Can't wait for the call. Would love to JeffAdams05 08/07/17 10:41:28 PM
#824   $MACK Daily and Weekly Ichimoku Chart http://s $Pistol Pete$ 07/24/17 03:07:42 PM
#823   This is a flipper stock until further notice CashFreeze 07/18/17 11:04:04 AM
#822   CashFreeze: you go on their website and redspinelpinktopaz 07/18/17 10:45:05 AM
#821   MACK drop has been on low volume. Picked CashFreeze 06/30/17 12:24:58 PM
#820   MACK buyer at $1.41 PigeonToad 06/28/17 02:47:27 PM
#819   Love this channel surfing on $MACK CashFreeze 06/28/17 12:56:31 PM
#818   $MACK Daily and Weekly Charts http://www.stock $Pistol Pete$ 06/27/17 07:40:37 PM
#817   To approve an amendment to our certificate of FreezeThese 06/26/17 11:24:30 AM
#816   MACK WILL BE ADDED TO .... RUSSELL list holdingfunder 06/23/17 08:37:57 AM
#815   Lone great minds think alike!!! I got in kevinraugust25 06/23/17 01:38:59 AM
#814   Another great play for us my man!! Lone Wolf 06/22/17 12:51:17 PM
#813   The squeeeze is on ;)))) europtiger 06/22/17 11:04:28 AM
#812   What a golden egg!! Sorry shorties!! $MACK Lone Wolf 06/22/17 10:13:09 AM
#811   Gapfill 3+ weeeee europtiger 06/22/17 10:04:35 AM
#810   Mack attack CashFreeze 06/22/17 10:02:50 AM
#809   Might Even see a squeeeze here at some Point europtiger 06/22/17 09:55:29 AM
#808   Looking Sweet! 1,38+ today b nice europtiger 06/22/17 09:50:38 AM
#807   Damn...I thought I had the best grab @ Lone Wolf 06/22/17 12:17:27 AM
#806   I have shares as low as 1.135. It CashFreeze 06/21/17 08:35:23 PM
#805   Yup...reversal confirmed. $MACK Lone Wolf 06/21/17 06:54:25 PM
#804   Lots of interest in those $1.3 shares. Lone Wolf 06/21/17 02:10:57 PM
#803   Really Looking good Hope i Got bottom Thx Buddy europtiger 06/21/17 10:13:56 AM
#802   Most def looking great here! Bottom affirmed Lone Wolf 06/21/17 08:29:54 AM
#801   Yep... because the cat is still alive ... holdingfunder 06/21/17 04:32:23 AM
#800   Cats do bounce ... evidently FreezeThese 06/20/17 12:43:34 PM
#799   Bought yesterday and today Could b turnaround here europtiger 06/20/17 11:09:47 AM
#798   * * $MACK Video Chart 06-19-17 * * ClayTrader 06/19/17 04:46:03 PM
#797   I see some possibility of a bounce ... holdingfunder 06/19/17 12:22:30 PM
#796   reverse Split, better leave jorbaespa 06/19/17 05:22:01 AM
#795   Lot of "T" trades at the end of roger wilco 06/16/17 06:46:21 PM
#794   Massive volume spike at end of day last CashFreeze 06/16/17 04:06:51 PM
#793   I don't see any material events that would roger wilco 06/16/17 11:33:16 AM
#792   I picked this up yesterday. The chart denotes CashFreeze 06/16/17 10:23:44 AM
#791   Great day for a reversal confirmation via a Lone Wolf 06/16/17 08:47:34 AM
#790   No news until 2018 jorbaespa 06/16/17 02:47:01 AM
#789   Fingers crossed that the "Outlook" conclusion works out ReadyToRumble 06/15/17 06:59:05 PM
#788   To be clear, they filed an extension to ReadyToRumble 06/15/17 06:50:39 PM
#787   Some decent activity here in the AH. Lone Wolf 06/15/17 04:52:08 PM
#786   Well...let me just say this...they expanded their management Lone Wolf 06/15/17 04:05:48 PM
#785   Time to buy! MACK @$1.15 Lone Wolf 06/15/17 03:04:55 PM
#784   hole market is down... holdingfunder 06/15/17 02:03:25 PM
#783   When will this pig stop falling? Good Lord CashFreeze 06/15/17 12:58:55 PM
#782   How far can you get the knife edge ???? jorbaespa 06/15/17 11:25:45 AM
#781   Looks like the bottom is in for Mack. Rock_nj 06/09/17 01:36:46 PM
#780   I think so $Pistol Pete$ 06/08/17 11:57:58 PM
#779   Issued a CT order? Jd62 06/08/17 04:33:59 PM
#778   Looks like we may have found bottom here! roger wilco 06/08/17 11:20:19 AM
PostSubject